Guillain-Barré syndrome triggered by influenza vaccination in a recipient of liver transplant on FK506

Liver Transplantation

Volumn 12, Issue 10, 2006, Pages 1537-1539

  Moon, Joon Shik ^a   Souayah, Nizar ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; PREDNISONE; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; COLON RESECTION; CYTOMEGALOVIRUS; DEATH; DEMYELINATING NEUROPATHY; DOWN REGULATION; DRUG BLOOD LEVEL; DYSPHAGIA; ELECTRODIAGNOSIS; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; GRAFT REJECTION; GUILLAIN BARRE SYNDROME; HERPES SIMPLEX VIRUS 1; HOSPITAL ADMISSION; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VIRUS; ISCHEMIC COLITIS; LIVER TRANSPLANTATION; LUMBAR PUNCTURE; MALE; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; NERVE CONDUCTION; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUADRIPLEGIA; RESPIRATORY TRACT INTUBATION; SEPTIC SHOCK; T LYMPHOCYTE; TREATMENT FAILURE;

FATAL OUTCOME; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA VACCINES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; VACCINATION;

EID: 33750138034     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20864     Document Type: Article

References (27)

1. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004;30:131-156.
2. Bulsara KR, Baron PW, Tuttle-Newhall JE, Clavien PA, Morgenlander J. Guillain-Barre syndrome in organ and bone marrow transplant patients. Transplantation 2001; 71:1169-1172.
3. El-Sabrout RA, Radovancevic B, Ankoma-Sey V, Van Buren CT. Guillain-Barre syndrome after solid organ transplantation. Transplantation 2001;71:1311-1316.
4. Taylor BV, Wijdicks EF, Poterucha JJ, Weisner RH. Chronic inflammatory demyclinating polyneuropathy complicating liver transplantation. Ann Neurol 1995;38:828-831.
5. Echaniz-Laguna A, Battaglia F, Ellero B, Mohr M, Jaeck D. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Muscle Nerve 2004;30:501-504.
6. Ayres RC, Dousset B, Wixon S, Buckels JA, McMaster P, Mayer AD. Peripheral neurotoxicity with tacrolimus. Lancet 1994.343:862-863.
7. Wilson JR, Conwit RA, Eidelman BH Starzl T, Abu-Elmagd K. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 1994;17:528-532.
8. Iwasaki Y, Ichikawa Y, Igarashi O, Iwamoto K, Kinoshitata M, Ikeda K. Neuroprotective actions of FK506 and cyclosporin A on motor neuron survival following neonatal axotomy. Neurol Res 2002;24:573-576.
9. Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke A. FK506 is neuroprotective in a model of anti-retroviral toxic neuropathy. Ann Neurol 2003;53:57-64.
10. Kvist M, Danielsen N, Dahlin LB. Effects of FK506 on regeneration and macrophages in injured rat sciatic nerve. J Peripher Nerv Syst 2003;8:251-259.
11. Birge RB, Wadsworth S, Akakura R, Abeysinghe H, Kanojia R, Maclelag M, et al. A role for schwarm cells in the neuroregenerative effects of a non-immunosuppressive fk506 derivative, jnj460. Neuroscience 2004:124:351-366.
12. Udina E, Rodriguez FJ, Verdu E, Espejo M, Gold BG, Navarro X. FK506 enhances regeneration of axons across long peripheral nerve gaps repaired with collagen guides seeded with allogeneic Schwann cells. Glia 2004;47:120-129.
13. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-1802.
14. Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and Guillain Barre syndrome small star, filled. Clin Immunol 2003;107:116-121.
15. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, Maurer JR. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 2001;18:971-976.
16. Larner AJ, Farmer SF. Myelopathy following influenza vaccination in inflammatory CNS disorder treated with chronic immunosuppression. Eur J Neurol 2000;7:731-733.
17. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? J Autoimmun 2000;14:1-10.
18. Duchini A, Hendry RM, Redfield DC, Pockros PJ. Influenza infection in patients before and after liver transplantation. Liver Transpl 2000;6:531-542.
19. Burbach G, Bienzle U, Stark K, Rayes N, Neuhaus R, Serke S, et al. Influenza vaccination in liver transplant recipients. Transplantation 1999;67:753-755.
20. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl 2001;7:311-313.
21. Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant 2004;4:1805-1809.
22. Sanchez-Fructuoso AI, Prats D, Naranjo P, Fernandez-Perez C, Gonzalez MJ, Mariano A, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000:69:436-439.
23. Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000;69:2449-2451.
24. Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant 1999;18:220-225.
25. Magnani G, Falchetti E, Pollini G, Reggiani LB, Grigoni F, Coccalo F, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005;24:588-592.
26. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005;366:1175-1181.
27. Centers for Disease Control and Prevention. High level of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 2006;55:44-46.